Testing for hepatitis B virus core antigen and e antigen may confer additional safety of donors' blood negative for heptitis B virus surface antigen Sir, Viral hepatitis B (HBV) is a major worldwide public health concern as it can be readily transmitted through blood transfusion, especially when blood collection would be performed during the window period. [1] The specific serologic markers for HBV testing include the hepatitis B surface antigen (HBsAg) and hepatitis B e-antigen (HBeAg), and the antibodies to hepatitis B core antigen and e-antigen (anti-HBc and anti-HBe). AntiHBc can be detected in people infected with HBV. HBeAg is associated with HBV infection and is found when there is active replication of virus. [2] This study was performed to test the positivity of serological markers in the blood of donors negative for HBsAg. Hence, the current study, performed at Hospital Tengku Ampuan Afzan, Kuantan, Malaysia, was carried out to determine the prevalence of anti-HBc, HBeAg, and anti-HBe among blood donors negative for HBsAg to detect potentially infectious blood units, and to help in deciding whether supplemental testing may result in additional safety to blood products. MONOLISA enzyme assays (MONOLISA, Bio-RAD Laboratories, France) were utilized to test for anti-HBc, HBeAg, and anti-HBe antibodies.
Out of 208 HBsAg-negative blood samples, 20 samples (9.6%) were found to be anti-HBc reactive. All these 20 samples were also positive for anti-HBe and were negative for HBeAg [ Tables 1 and 2 ]. Furthermore, the prevalence of positivity was found to be higher among regular donors compared with new donors [ Table 3 ].
Although exposure to HBV may be followed by full recovery, it is still advisable to defer these anti-HBc-positive donors, at least temporarily. Furthermore, it can be suggested that testing for antiHBc be introduced routinely for all blood samples, especially in Asian countries where the prevalence of HBV infection is generally higher than that in European and North American countries. [3] The high frequency of post-transfusion hepatitis is apparently because HBsAg circulates at undetectable levels for current screening assays; hence, screening for anti-HBc antibody is necessary. [4] This will increase the safety and reduce the risk of disease transmission during blood transfusion; however, it has a drawback in that it may also lead to a sharp increase in the rejection rates and may be responsible for an increase in the total costs. Thus, such a screening program can be substantiated by long-term follow-up of donors deferred for this reason, to monitor them for viral loads and/or development of clinical disease. 
Seropositive status of dengue virus infection among blood donors in North Malaysia
Sir, Dengue virus (DENV) infection is a tropical disease causing morbidity and mortality. It is endemic in certain regions of Malaysia causing major public health problems. [1] It is transmitted largely through vector mosquito Aedes aegypti. The viremia among blood donors was reported from the endemic area of South American region. [2] In order to assess the magnitude of viremia among our blood donors, we screened serum samples from 360 random donors selected in a consecutive manner from blood donations during an outbreak of the disease from December 2009 to January 2010. Sample size was determined using online software sample size calculator for prevalence studies. [3] Commercial kits (PanBio, Australia) were used for detection of anti-DENV.
Among 166 seropositive donors, 141 donors had Immunoglobulin G (IgG) anti-DENV while 15 donors had Immunoglobulin M (IgM) antibody and 10 donors displayed the dual specificities of IgG and IgM antibody [ Table 1 ].
Presence of IgG may indicate the previous exposure of the DENV while IgM may point to the current ongoing infection suggesting that the donor is in a carrier stage of the virus. It is conceivable that blood from such donor may potentially transmit the infection to the recipients.
Transfusion transmitted DENV has been documented, [4] yet the infection is not considered as transfusion transmitted disease (TTD). As blood units are not routinely screened for DENV, seropositive units may possibly transmit DENV to prospective recipients. Such reports bring an attention to the stake holders in blood transfusion practice to consider DENV as a potential threat to transfusion safety. The data presented with seropositive status among blood donors is during peak seasons of DENV infection. However, there is no data available during the lean season as control/ cohort study to assign its strategic significance in testing the donor units in routine.
Reported study is based on expensive technology to detect viral ribonucleic acid, [4] that may not be affordable as a routine screening tool for average blood banks in countries with limited financial resources. However, screening for IgM anti-DENV is feasible through available facility meant for screening other TTDs in blood bank set up. It is worth noting that, although discarding DENV seropositive units would affect blood stock inventory, nonetheless, transfusion safety is of paramount importance for the recipient. 
